VBIO: AFRRI/NIAID Tests Entolimod
AFRRI/NIAID designs protocol to evaluate Valion Bio's Entolimod as treatment for GI-ARS
VBIO - AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS